Form 4: Teladoc Health's Chief Technology Officer Reports Stock Transactions
SEC Form 4 Filing
Nikolaos P. Nanis, Chief Technology Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities.
Summary
- Nikolaos P. Nanis, the Chief Technology Officer of Teladoc Health, filed a Form 4 detailing changes in beneficial ownership.
- On August 30, 2024, Nanis acquired shares of common stock through the conversion of performance stock units (370 shares) and restricted stock units (506, 894, and 1,085 shares).
- On September 3, 2024, Nanis disposed of 1,033 shares of common stock at a price of $7.164 per share.
- Following these transactions, Nanis directly owns 75,410 shares of Teladoc Health common stock.
- Nanis also holds derivative securities, including 2,218 Performance Stock Units, 1,012 Restricted Stock Units from a March 1, 2022 grant, 2,684 Restricted Stock Units from a June 1, 2022 grant, and 6,511 Restricted Stock Units from a March 3, 2023 grant.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as an indicator of management's view of the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Reporting person was granted 6,064 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 06/01/2022 | Reporting person was granted 10,730 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/03/2023 | Reporting person was granted 13,021 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/01/2024 | One-third of the performance stock units vest on this date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 08/30/2024 | Date of stock acquisitions via conversion of performance and restricted stock units. |
| 09/03/2024 | Date of stock disposal. |
| 09/04/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.